Aviragen Therapeutics, Inc. (NASDAQ:AVIR)‘s stock had its “hold” rating restated by analysts at HC Wainwright in a research report issued on Monday.

Aviragen Therapeutics (NASDAQ AVIR) opened at $0.58 on Monday. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.76 and a quick ratio of 6.76. Aviragen Therapeutics has a one year low of $0.43 and a one year high of $1.60.

TRADEMARK VIOLATION WARNING: “HC Wainwright Reaffirms “Hold” Rating for Aviragen Therapeutics, Inc. (AVIR)” was reported by Daily Political and is the property of of Daily Political. If you are reading this report on another publication, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be viewed at https://www.dailypolitical.com/2017/11/06/hc-wainwright-reaffirms-hold-rating-for-aviragen-therapeutics-inc-avir.html.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Virtu KCG Holdings LLC bought a new stake in Aviragen Therapeutics during the 2nd quarter worth about $149,000. FMR LLC lifted its position in Aviragen Therapeutics by 0.3% during the 2nd quarter. FMR LLC now owns 1,005,345 shares of the biotechnology company’s stock worth $673,000 after buying an additional 2,845 shares in the last quarter. Finally, Carlson Capital Management bought a new stake in Aviragen Therapeutics during the 2nd quarter worth about $105,000. 24.20% of the stock is owned by hedge funds and other institutional investors.

About Aviragen Therapeutics

Aviragen Therapeutics, Inc, formerly Biota Pharmaceuticals, Inc, is focused on the discovery and development of direct-acting antivirals to treat infections that affect patients globally. The Company has three product candidates in clinical development that address viral infections that have limited therapeutic options.

Receive News & Ratings for Aviragen Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aviragen Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.